Overview

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

Status:
Completed

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

Summary

The present study will give information about the course over time in skeletal-related events (SRE) in prostate cancer patients with bone metastases treated with zoledronic acid 4 mg administered as a 15-minute infusion every 4 weeks for a maximum of 15 infusions. The protocol will enroll patients with recent diagnosis of bone metastases from prostate cancer who are hormone-refractory, hormone-naïve or still hormone-sensitive, that represent the entire population of prostate cancer patients

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Collaborator:

Società Italiana di Urologia (SIU)

Treatments:

Diphosphonates
Hormones
Zoledronic Acid